Array-based comparative genomic hybridization characterizes a deletion associated with a t(15;17) in acute promyelocytic leukemia

American Journal of Clinical Pathology

Volumn 130, Issue 5, 2008, Pages 818-823

  Dolan, Michelle ^a   Peterson, Bruce ^a   Hirsch, Betsy ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Clinical pathology; Genetics; Hematopathology

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CASE REPORT; CHROMOSOME 17; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENOME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; CHROMOSOME 15; DNA MICROARRAY; FATALITY; GENE DELETION; GENE TRANSLOCATION; GENETICS; MIDDLE AGED; RECURRENT DISEASE;

CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; FATAL OUTCOME; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECURRENCE; SEQUENCE DELETION; TRANSLOCATION, GENETIC;

EID: 55249083736     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPENMUI47OGKRW     Document Type: Article

References (33)

1. Popenoe DW, Schaefer-Rego K, Mears JG, et al. Frequent and extensive deletion during the 9,22 translocation in CML. Blood. 1986;68:1123-1128.
2. Shtalrid M, Talpaz M, Kurzrock R, et al. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood. 1988;72:485-490.
3. Dewald GW, Wyatt WA, Silver RT. Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. Leuk Lymphoma. 1999;34:481-491.
4. Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poorprognosis subgroup of patients with chronic myeloid leukemia. Blood. 2000;95:738-744.
5. Huntly BJP, Reid AG, Bench AJ, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood. 2001;98:1732-1738.
6. Huntly BJP, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood. 2003;102:1160-1168.
7. Gonzalez FA, Anguita E, Mora A, et al. Deletion of BCR region 3′ in chronic myelogenous leukemia. Cancer Genet Cytogenet. 2001;130:68-74.
8. Huntly BJP, Guilhot F, Reid AG, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood. 2003;102:2205-2212.
9. Lee YK, Kim YR, Min HC, et al. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia. Cancer Genet Cytogenet. 2006;166:65-73.
10. de Campos MGV, Montesano FT, Rodrigues MM, et al. Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia. Cancer Genet Cytogenet. 2007;178:49-56.
11. Yoong Y, VanDeWalker TJ, Carlson RO, et al. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia. Eur J Haematol. 2005;74:124-127.
12. Kolomietz E, Marrano P, Yee K, et al. Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia. 2003;17:1313-1323.
13. Douet-Guilbert N, Morel F, Quemener S, et al. Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia. Cancer Genet Cytogenet. 2006;170:89-92.
14. Kolomietz E, Al-Maghrabi J, Brennan S, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood. 2001;97:3581-3588.
15. Bacher U, Schnittger S, Kern W, et al. The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia. Haematologica. 2005;90:558-559.
16. Moon HW, Chang YH, Kim TY, et al. Incidence of submicroscopic deletions vary according to disease entities and chromosomal translocations in hematologic malignancies: investigation by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2007;175:166-168.
17. Konig M, Reichel M, Marschalek R, et al. A highly specific and sensitive fluorescence in situ hybridization assay for the detection of t(4;11)(q21;q23) and concurrent submicroscopic deletions in acute leukemias. Br J Haematol. 2002;116:758-764.
18. Kuss BJ, Deeley RG. Deletion of gene for multidrug resistance in acute myeloid leukemia with inversion in chromosome 16: prognostic implications. Lancet. 1994;343:1531-1534.
19. van der Kolk DM, Vellenga E, van der Veen AY, et al. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. Blood. 2000;95:3514-3519.
20. Döhner K, Schlenk RF, van der Reijden BA, et al. Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact [letter]. Leukemia. 2000;14:1154.
21. Marlton P, Claxton DF, Liu P, et al. Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis. Blood. 1995;85:772-779.
22. Specchia G, Albano F, Storlazzi CT, et al. T(15;17) in acute promyelocytic leukemia is not associated with submicroscopic deletions on der(17). Haematologica. 2002;87:775-777.
23. Subramaniyam S, Nandula SV, Nichols G, et al. Do RARA/ PML fusion gene deletions confer resistance to ATRA-based therapy in patients with acute promyelocytic leukemia? Leukemia. 2006;20:2193-2195.
24. Powell BL, Moser BK, Stock W, et al. Preliminary results from the North American Acute Promyelocytic Leukemia (APL) study C9710 [abstract]. Blood. 2006;108:566.
25. Shaffer LG, Tommerup N. eds. ISCN 2005: An International System for Human Cytogenetic Nomenclature (2005). Basel, Switzerland: S Karger; 2005.
26. Karolchik D, Kuhn RM, Baertsch R, et al. The UCSC Genome Browser Database: 2008 update. Nucleic Acids Res. 2008;36:D773-D779.
27. Hosokawa Y, Maeda Y, Takahashi E, et al. Human aiolos, an ikaros-related zinc finger DNA binding protein: cDNA cloning, tissue expression pattern, and chromosomal mapping. Genomics. 1999;61:326-329.
28. Katayama N, Kita K, Kawakami K, et al. Granulocyte colony-stimulating factor and its receptor in acute promyelocytic leukemia. Am J Hematol. 1998;58:31-35.
29. Jansen JH, de Ridder MC, Geertsma WMC, et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood. 1999;94:39-45.
30. Dayton AI, Selden JR, Laws G, et al. A human c-erbA oncogene homologue is closely proximal to the chromosome 17 breakpoint in acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1984;81:4495-4499.
31. Gonzalez-Sancho JM, Garcia V, Bonilla F, et al. Thyroid hormone receptors/THR genes in human cancer. Cancer Lett. 2003;192:121-132.
32. Liang C, Stillman B. Persistent initiation of DNA replication and chromatin-bound MCM proteins during the cell cycle in cdc6 mutants. Genes Dev. 1997;11:3375-3386.
33. Clay-Farrace L, Pelizon C, Santamaria D, et al. Human replication protein Cdc6 prevents mitosis through a checkpoint mechanism that implicates Chk1. EMBO J. 2003;22:704-712.